Actively Recruiting
Maintenance Venetoclax in AML Fit Patients
Led by Sohag University · Updated on 2025-11-24
80
Participants Needed
2
Research Sites
104 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
this study will explore the efficacy of maintenance SC cytarabine + venetoclax therapy as regard disease free survival (DFS) in AML fit patients who achieved CR after highly aggressive chemotherapy as bridge for BMT or if BMT will be delayed or canceled due to any other reason.
CONDITIONS
Official Title
Maintenance Venetoclax in AML Fit Patients
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 to 60 years
- Newly diagnosed AML patients who achieved complete remission after first-line chemotherapy
- Refractory or recurrent AML patients who achieved complete remission after second-line chemotherapy
- Patients not eligible for immediate bone marrow transplantation
You will not qualify if you...
- Patients who have not achieved complete remission
- Patients younger than 18 or older than 60 years
- Patients eligible for immediate bone marrow transplantation
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
Sohag university hospital
Sohag, Egypt
Actively Recruiting
2
Sohag university
Sohag, Egypt
Actively Recruiting
Research Team
E
Eman I Abdelshakour, Asst lect
CONTACT
W
Walaa G Mohamed, Lecturer
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
TRIPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here